Interaction Checker Methodology

Overview

The HerbOS Interaction Checker is an educational tool designed to help users identify potential interactions between herbal supplements and pharmaceutical drugs. It cross-references a curated database of 568+ herbs against 288 pharmaceuticals, surfacing clinically relevant interaction data drawn from peer-reviewed literature. This tool is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to any medication or supplement regimen.

Data Sources

Our interaction data is compiled and cross-referenced from the following authoritative sources: • PubMed / MEDLINE — The primary biomedical literature database maintained by the U.S. National Library of Medicine. We reference published clinical trials, systematic reviews, and case reports. • Natural Medicines Database — The most comprehensive evidence-based resource for natural products, providing interaction severity ratings and clinical significance assessments. • World Health Organization (WHO) Monographs on Selected Medicinal Plants — WHO-authored monographs covering safety, efficacy, and pharmacological profiles of widely used medicinal plants. • European Medicines Agency (EMA) — Herbal monographs and assessment reports published by the EMA’s Committee on Herbal Medicinal Products (HMPC). • American Herbal Pharmacopoeia (AHP) — Peer-reviewed monographs providing quality control standards, therapeutic information, and safety data for botanical medicines. • Lexicomp — Clinical drug information database used widely in hospital and pharmacy settings, including natural product interaction data. • FDA MedWatch — The FDA’s safety reporting system for adverse events, product problems, and medication errors involving dietary supplements and drugs.

Evidence Classification

Each interaction in our database is tagged with an evidence level reflecting the strength of the supporting research. We use a five-tier hierarchy: 1. Meta-analysis / Systematic Review (Highest) Pooled analyses of multiple studies providing the strongest level of evidence. These are considered the gold standard for evaluating clinical significance. 2. Randomized Controlled Trial (RCT) Well-designed trials with randomization, blinding, and control groups. RCTs in human subjects provide strong evidence for or against a given interaction. 3. Clinical Trial / Observational Study Non-randomized clinical trials, cohort studies, case-control studies, and cross-sectional analyses. These provide moderate evidence and may identify interactions seen in real-world clinical populations. 4. Animal Study Preclinical research conducted in animal models. While valuable for understanding mechanisms of action, animal data does not always translate directly to human outcomes. 5. In Vitro / Traditional Use (Lowest) Laboratory studies conducted in cell cultures or test tubes, as well as interactions suggested by historical or traditional use patterns. These provide preliminary evidence that may warrant further investigation.

Severity Ratings

Interactions are assigned one of four severity ratings: Contraindicated — The combination should be avoided entirely. Evidence indicates a high risk of serious adverse effects, therapeutic failure, or life-threatening outcomes. Severe — The interaction may result in clinically significant harm. Close monitoring by a healthcare professional is essential, and the combination should generally be avoided unless the benefit clearly outweighs the risk. Moderate — The interaction may alter the efficacy or safety profile of one or both substances. Monitoring is recommended, and dosage adjustments may be necessary. Mild — The interaction is unlikely to cause significant clinical effects in most individuals. Awareness is recommended, but no specific action is usually required.

Clinical Significance Assessment

Not every pharmacological interaction identified in a laboratory setting translates into a meaningful clinical outcome. Our clinical significance assessment considers: • Dose-dependency — Whether the interaction is only relevant at specific dosages or concentration ranges. • Route of administration — Oral, topical, and intravenous routes may produce different interaction profiles. • Population factors — Age, hepatic and renal function, genetic polymorphisms, and polypharmacy status can all influence whether an interaction manifests clinically. • Temporal relationship — Whether the substances need to be taken concurrently or whether the interaction persists after discontinuation. • Therapeutic index — Drugs with a narrow therapeutic index (e.g., warfarin, digoxin, lithium) are flagged for heightened scrutiny even when evidence is limited.

Limitations

When to Seek Professional Help

Always consult a qualified healthcare provider — such as a physician, pharmacist, naturopathic doctor, or clinical herbalist — before starting, stopping, or changing any herbal supplement, especially if you are: • Currently taking prescription medications • Pregnant or breastfeeding • Scheduled for surgery • Managing a chronic condition • Taking medications with a narrow therapeutic index (e.g., warfarin, lithium, digoxin) If you experience any adverse effects that you suspect may be related to an herb-drug interaction, seek medical attention immediately.

Report Inaccurate Data

We are committed to maintaining the accuracy and currency of our interaction data. If you identify an error, outdated information, or a missing interaction that you believe should be included, please contact our clinical team: clinical@herbos.app Please include the herb name, drug name, and a reference to the supporting evidence when possible. We review all submissions and update our database regularly.